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The repeated difficulties of translation from bench to bedside for a number of acute stroke therapies, and the undoubted retreat from this area of research by many pharmaceutical companies must lead us to question the fundamental tenets of our translational assumptions. This applies particularly to ischemic stroke, the ischemic cascade and neuroprotection. Are the animal models appropriate? Do we really understand the ischemic cascade? Are there other novel approaches yet to be explored? How can we improve the efficiency and standards of our research? Can this be done within an ethical framework? Too many questions? Probably not enough! We really need to stretch ourselves, think outside the box, while being necessarily self-critical of our past performances. In this themed edition.
David Howells and Malcolm McLeod, have put together a superb series of articles where many of these questions are addressed.
Personally, I feel that translational research in stroke is alive and well. We now have four proven acute interventions of proven benefit and at least six interventions similarly qualified for primary and secondary prevention. Most of these have come via a translational route to their present position in the panoply of stroke therapies; albeit not always traditional but nevertheless translational. However, for acute ischemic stroke I think it's time for more bench than bedside, but the latter will come fast enough.
Translational research
David W. Howells and Malcolm R. MacLeod Science advances the human condition with a mix of blue-sky curiosity and driven and highly focussed translational research. Stroke research is a relative newcomer to this endeavour. Until the last few decades there was little to be done to prevent the deaths of those most severely affected or to ameliorate the disability of most of the survivors. Those who naturally survived relatively unscathed made clinical trial design difficult if the treatment being studied entailed the possibility of harm.
Clinical and basic science translational research has changed this dramatically. Advances in the physical sciences have provided us with medical imaging modalities, used first in a research context then increasingly in routine clinical practice, to help decide who to treat and with what approach. Protein chemistry, enzymology, pharmacology and molecular biology have delivered drugs that control the co-morbidities which increase stroke risk, drugs to reduce the risk of thromboembolus formation and drugs and surgical methods to remove the thromboemboli which precipitate acute injury.
Animal testing has played a critical part in this process and it matters little what the title on the banner above the laboratory door was.
We are entering an era of great promise. True, we have had difficulties. But while often painful, self-critique is slowly and surely shining a light on our route forward. Standing on the bridge between experimental animal research and clinical research I am struck, not by the differences, but by the overwhelming similarities between laboratory and clinical stroke. In this series of reviews eminent and up-and-coming laboratory and clinical researchers cast a critical eye over their areas of stroke expertise, areas of consensus are discussed and gaps in our knowledge put under the spotlight.
Recent advances in genomics, proteomics and laboratory detection methodologies have led to resurgence in the search for biomarkers that might aid diagnosis and therapeutic decision making. This search is taking place both in animals and man. Whiteley et al. provide an excellent review of the current state of play of this emerging field. If the children in the back seat of the car asked "are we there yet" the answer is still no, but we are getting closer. Combining good clinical profiling with the agnostic technologies that allow us to search the entire genome and proteome, without the bias brought to the table by our personal favourite molecule, seems likely to provide the key.
While the search for biomarkers provides one route to improving stroke outcome, designing drugs that target the pathophysiology of stroke is another. To be able to do this we must have laboratory models of stroke. It would be both impractical and unethical to expose patients to every new candidate drug before we knew it was safe and had evidence for probable efficacy. Kraft et al. describe the different animal models of stroke and how they fill different niches in the aetiology of stroke. They remind us that no single model covers all the bases and that the model chosen for both blue sky and pre-clinical investigations depends on the specific hypotheses being tested. These hypotheses are dictated by both the molecular biology of the cell and the environment within which it exists. Changhong Xing et al. describe the processes critical for brain damage after stroke and remind us of both the importance of white matter to the functional integrity of the mammalian brain and of the role played by microglia in both evolution of damage and it's repair. Both represent therapeutic targets where we still have much to learn. Ankolekar et al. highlight the importance of environment on outcome, describing the impact of co-morbidities common to human stroke. Individual co-morbidities clearly worsen the impact of stroke in both animals and humans but we know little of how the common co-morbidities interact. Translational success may ultimately depend on a thorough knowledge of the impact of co-morbidity on the limits of candidate drug actions.
Sutherland et al, provide an elegant review of past attempts at drug development for stroke and the current state of play. The future holds promise not only for old favourites like hypothermia which is gaining traction as a neuroprotectant in related fields, but also for newly discovered targets like NAAPH oxidases. Importantly they remind us that other fields have made great leaps forward, even with imperfect models of disease. Sinden and Muir extend this theme with a review of the challenges and opportunities promised by stem cells as a therapeutic for stroke. Whether these cells will ultimately provide a supportive environment or true tissue reconstitution remains to be seen. The latter is obviously an ambitious aim for stroke therapy, yet in other fields with "simpler" tissues we see a steady march towards this goal. Even in neuroscience, the stem cell capacity for integration into simple circuits seems more robust with each experiment.
Finally we return to the two articles discussing the ethics and practicalities of stroke translational research. While these might seem strange bedfellows they are not. Levy takes a philosophical approach arguing the case for and against the use of animals to benefit humans, concluding that research is justified only when researchers have a well-justified belief that their research will significantly help us respond to urgent problems.
The level of such justification, and cost-effective strategies for reaching it before progress to clinical trial are suggested by Howells and Macleod et al. Human stem cell technology can be utilized to screen for drugs that interact with human molecular targets. Where there is existing data, the tools of systematic review and meta-analysis should be used to ensure an explicit understanding of therapeutic potential. Where new data is required, animal research should be of the very highest standard to avoid the misleading impact of bias and have the statistical power to provide definitive results. Furthermore it may be practical to adapt the multi-centre and harmonised data analysis techniques of human clinical trialling to provide more effective animal experimentation. Perhaps surprisingly better organised pre-clinical research will be less expensive, use fewer animals in the long run and deliver effective stroke drugs more rapidly.
